ScholarLens Back to search
2023•Journal of Nuclear MedicineOpen access

The Latest Advances in Peptide Receptor Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors

Elif Hindié, Éric Baudin, Rodney J. Hicks, David Taïeb

Open full text 5 citations

Abstract

We would like to draw attention to the latest advances in the field of peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) of gastroenteropancreatic origin. The term NET refers to well-differentiated tumors that can be grade 1 (Ki-67 index, <3), 2 (Ki-67, 3–20), or 3 (Ki-

Open-access reader

About this research paper

What this paper is about

We would like to draw attention to the latest advances in the field of peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) of gastroenteropancreatic origin. The term NET refers to well-differentiated tumors that can be grade 1 (Ki-67 index, <3), 2 (Ki-67, 3–20), or 3 (Ki-

Why it matters

OpenAlex reports 5 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

We would like to draw attention to the latest advances in the field of peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) of gastroenteropancreatic origin. The term NET refers to well-differentiated tumors that can be grade 1 (Ki-67 index, <3), 2 (Ki-67, 3–20), or 3 (Ki-

Key concepts: Peptide receptor, Radionuclide therapy, Neuroendocrine tumors, Medicine, Cancer research, Radionuclide, Peptide, Receptor

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
The Latest Advances in Peptide Receptor Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors — Research Paper | ScholarLens